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A B S T R A C T
Aluminium phosphate is a commonly used adjuvant consisting of heterogeneously sized aggregates up to several
micrometers. However, aluminium phosphate nanoparticles may exhibit an improved adjuvant effect. In this
study, nanoparticles were made by sonication of commercially available aluminium phosphate adjuvant, re-
sulting in particles with a size (Z-average diameter) between 200–300 nm and a point of zero charge of 4.5. To
prevent reaggregation, which occurred within 14 days, a screening of excipients was performed to identify
stabilisers effective under physiological conditions (pH 7.4, 290 mOsm). The amino acids threonine, asparagine,
and L-alanyl-L-1-aminoethylphosphonic acid (LAPA) stabilised sonicated aluminium phosphate. Particle sizes
remained stable between 400–600 nm at 37 °C during 106 days. Contrarily, arginine induced strong reag-
gregation to a particle size larger than 1000 nm. The stability of aluminium phosphate nanoparticles was
strongly affected by the pH. Aggregation mainly occurred below pH 7. The adsorption capacity, a potentially
relevant parameter for adjuvants, was slightly reduced in the presence of asparagine, when using a model an-
tigen (lysozyme). LAPA, arginine, threonine and aspartic acid reduced protein adsorption significantly. The
adjuvant effect of aluminium phosphate nanoparticles was studied by immunisation of mice with diphtheria
toxoid adjuvanted with the aluminium phosphate nanoparticles. The presence of LAPA, threonine, aspartic acid
or asparagine did not alter diphtheria toxoid-specific antibody or toxin-neutralising antibody titres. Arginine
increased diphtheria toxoid-specific antibody titres but not toxin-neutralising antibody titres. In conclusion,
aluminium phosphate nanoparticles were stabilised by particular amino acids and induced an adjuvant effect
comparable to that of aluminium phosphate microparticles.
1. Introduction
Adjuvants augment the immune response against an antigen. The
most commonly used adjuvants for human vaccines are aluminium
salts, i.e. aluminium phosphate and aluminium hydroxide [1], [2]. Both
adjuvants aggregate to form colloidal particles of a few micrometers in
size in water [3], [4]. Aluminium salt-based adjuvants improve the
development of immunological memory after vaccination by mod-
ulating the uptake [5] and presentation of antigens [6] and by enhan-
cing the humoral immune response [7]. Aluminium salts adsorb anti-
gens mainly via electrostatic interactions or ligand binding [8]. Antigen
adsorption influences the stability of the antigen [9], the immune re-
sponse [9–11] and the cellular uptake and presentation of the antigen
[12]. The adsorption degree of vaccine antigens is determined for batch
release of vaccines that contain an aluminium salt-based adjuvant. The
adsorption capacity is influenced by many factors, such as the charge
and size of both the adjuvant and the antigen. Moreover, the surface
area of aluminium salt-based adjuvants is very important for protein
adsorption [13]. In principle, the surface area increases as the particle
size decreases. Besides its effect on antigen adsorption capacity, the
particle size of particulate adjuvants is also an important parameter for
the immune response. The cellular uptake of particles in general is re-
lated to their size and cellular uptake routes differ between small and
large particles [14], [15], which may affect the resulting immune re-
sponses. For instance, Li et al. reported that the specific antibody re-
sponses are stronger and last longer after s.c. immunisation with alu-
minium hydroxide nanoparticles compared to immunisation with
aluminium hydroxide micro particles, and relate these effects to in-
creased antigen adsorption and increased uptake of the adjuvant-an-
tigen complex by APCs when using nanoparticles compared to micro
particles [16].
Because the size of a particle may be important for its adjuvant
effect, nanoparticles may be beneficial over micro particles as vaccine
adjuvant. For instance, it may be possible to decrease the adjuvant dose,
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leading to a reduction in the side effects of aluminium salt-based ad-
juvants, such as local irritation and inflammation [16]. However, ag-
gregation of nanoparticles is sometimes difficult to overcome. Several
factors influence particle aggregation, such as the presence of salts and
the pH of the dispersion [17], [18]. Stabilisers can be used to prevent
aggregation, for example, by electrostatic or steric stabilisation. For
instance, stabilisers may increase the absolute value of the zeta po-
tential of the particles [19], which in turn improves their colloidal
stability. An increased zeta potential may also enhance antigen ad-
sorption. However, the use of a stabiliser might have a negative impact
on the immune response.
The aim of the current study was to produce stable aluminium
phosphate nanoparticles that can be used as vaccine adjuvant. To this
end, nanoparticles were prepared by sonication of commercially avail-
able aluminium phosphate adjuvant. The aluminium phosphate nano-
particles were stabilised under physiological conditions, i.e. 290 mOsm
and pH 7.4, by using particular amino acids. Subsequently, the me-
chanism of stabilisation was studied and the influence of sonication and
the presence of stabilisers on the adsorption degree of a model antigen,
lysozyme, was investigated. In addition, an immunisation study in mice
showed that diphtheria toxoid adjuvanted with stabilised aluminium
phosphate nanoparticles or commercially available adjuvant showed si-
milarly high diphtheria toxoid-specific antibody responses.
2. Materials and methods
2.1. Chemicals
Aluminium phosphate (Adju-Phos 2%, batches 7224, 9073, 9129,
9297, 9394) was purchased from Brenntag Biosector. The amino acids
L-alanine, L-arginine hydrochloride, L-asparagine, L-aspartic acid, L-
glutamic acid, L-glutamine, glycine, L-histidine hydrochloride, L-iso-
leucine, L-leucine, L-lysine hydrochloride, L-methionine, L-phenylala-
nine, L-proline, L-serine, L-threonine, trans-4-hydroxy-L-proline, L-va-
line, L-alanyl-L-1-aminoethylphosphonic acid (LAPA) and sucrose were
purchased from Sigma-Aldrich. Lysozyme was obtained from Sigma-
Aldrich. Diphtheria toxoid (DIF04-44, 4500 Lf/mL in 0.9% (w/v) NaCl)
was produced in house.
2.2. Preparation of aluminium phosphate nanoparticles
Nanoparticles of aluminium phosphate were prepared by sonication
of commercially available aluminium phosphate. Sonication was per-
formed by using a sonifier with a 3-mm tapered microtip coupled to a
½” disrupter horn (SonifierTM S-450, Branson Ultrasonics, Emerson).
Volumes of 10mL undiluted aluminium phosphate were sonicated
while cooling on ice for the time indicated with a pulse ratio on/off of
1 s/2 s at an intensity of 385W. To prevent sample contamination as a
result of tip erosion, a new tip was used for each sonication. Particle
size was measured immediately after each sonication using dynamic
light scattering (DLS) as described. Only batches with a Z-average
diameter smaller than 400 nm were used. Sonicated aluminium phos-
phate was used immediately after size measurements.
2.3. Stability study of sonicated aluminium phosphate nanoparticles
To study the stability of sonicated aluminium phosphate, one vo-
lume of 200mM amino acid solution in ultrapure water was mixed with
two volumes of sonicated aluminium phosphate dispersion containing
1.7 mg/mL Al3+ ions. The pH was adjusted to 7.4 by using 1M of so-
dium hydroxide (NaOH) or 1M of hydrochloric acid (HCl). To prevent
bacterial contamination, samples were prepared aseptically by using a
biohazard cabinet, cleaning utensils with alcohol and using sterile
starting materials. The osmolality was measured by using an osmometer
(Osmomat 3000, Gonotec GmbH). The osmolality was adjusted to 290
mOsm by adding an appropriate volume of 700mM sucrose solution
that was previously adjusted with 1M of NaOH or 1M of HCl to pH 7.4.
The volume was adjusted to four volumes with ultrapure water.
Samples were incubated at 37 °C for a maximum of 106 days.
2.4. Determination of particle size
The size (Z-average diameter) of sonicated aluminium phosphate
particles was measured by DLS on a Zetasizer Nano ZS (Malvern
Instruments Ltd.). Aliquots of 60 μL of each sample containing 10 μg/
mL Al3+ ions diluted in ultrapure water was measured in single-use
polystyrene UV micro cuvettes (BRAND®) at 25 °C. The Dispersion
Technology Software (version 7.11) was used for collection and ana-
lysis of the data. Each sample was measured in triplicate with an au-
tomatic attenuator. The number of runs and the measurement duration
were automatically optimised by the software.
2.5. Determination of zeta potential
The zeta potential of sonicated aluminium phosphate particles was
measured by using a Zetasizer Nano ZS (Malvern Instruments Ltd.).
Folded capillary cells (DTS1070, Malvern Instruments Ltd.) were filled
with sample containing 0.85mg/mL Al3+ at 25 °C. The Dispersion
Technology Software (version 7.11) was used for collection and ana-
lysis of the data. Zeta potential values were calculated according to the
Smochulowski equation. Each sample was measured in quadruplicate
with an automatic attenuator. The number of runs and the measure-
ment duration were automatically optimised by the software.
2.6. Adsorption of amino acids to aluminium phosphate
The binding of amino acids to sonicated aluminium phosphate
particles was studied by quantification of free amino acid in a mixture
containing 1.7 mg/mL Al3+ ions of aluminium phosphate nanoparticles
and 100 μM amino acid. After overnight incubation at room tempera-
ture, the samples were centrifuged at 16,000g for 15min. The amount
of free amino acid in the supernatants was determined by reversed
phase high-performance liquid chromatography (RP-HPLC). The free
amino acid molecules were derivatised with ortho-phthalaldehyde/9-
fluorenyl methyl chloroformate and quantified with fluorescence de-
tection. An internal standard containing 0.05M norvaline and 0.05M
sarcosine was added to correct for the loss of sample during the ex-
periment. Chromatographic analysis was performed on an RP-HPLC
system equipped with a Zorbax Eclipse Plus C18 column (2.1 x 150mm
3.5 μm, Agilent Technologies), Zorbax Eclipse Plus C18 guard
(2.1 x 12.5mm 5 μm Agilent Technologies), column oven (Hewlett
Packard), pump (Hewlett Packard), auto sampler (Hewlett Packard),
degasser (Hewlett Packard) and fluorescence detector (Agilent
Technologies). Mobile phases used were 10 nm Na2HPO4, 10mM
Na2B4O7 pH 8.2 and 5 nM NaN3 (solvent A) and methanol: acetonitrile:
water at a ratio of 45:45:10 (v:v:v) (solvent B). The gradient was in-
itiated with 5% solvent B at a flow of 0.420mL/min. The flow was
maintained and the sample was eluted by a linear gradient from 5 to
55% solvent B in 21min. Subsequently, the column was flushed for
4min with 100% solvent B with a flow rate of 0.600mL/min and then
equilibrated to the initial conditions. The Agilent OpenLAB
Chromatography Data System (CDS) ChemStation Edition Version
C.01.06 75 (Agilent Technologies) software was used for data acquisi-
tion and mathematical calculations. The adsorption of amino acids to
aluminium phosphate was calculated by subtracting the amount of free
amino acid in the supernatant from the amount of amino acid that was
added.
2.7. Adsorption degree of lysozyme to aluminium phosphate nanoparticles
in the presence of amino acids
The amount of lysozyme adsorbed to aluminium phosphate
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nanoparticles in the presence of amino acids was determined.
Therefore, NHS-Fluorescein (5/6-carboxyfluorescein succinimidyl
ester, ThermoFisher) was coupled to lysozyme by mixing in a molar
ratio of 2:1. The mixture was allowed to react at room temperature
while rotating for two hours. Free fluorescein was removed by using
disposable PD-10 desalting columns (GE Healthcare). The purified, la-
belled protein was used to determine the influence of amino acids on
the adsorption of lysozyme to aluminium phosphate. Solutions with
different amounts of protein were mixed with aluminium phosphate
dispersions. The final Al3+ concentration was 0.85mg/mL and the
protein concentration ranged from 0 to 4.5 mg/mL. Samples were in-
cubated for one hour at room temperature in a rotary mixer. The
samples were centrifuged at 16,000g for 15min. Supernatants were
added to a black, V-bottom 96-wells plate (Greiner Bio-One) in a two-
fold dilution (100 μL/well). The amount of lysozyme in the super-
natants and added protein concentrations was detected by fluorescence
at an excitation of 494 nm and emission of 518 nm by using a
SynergyMx reader (BioTek). The amount of lysozyme that was present
in the samples was calculated with Gen5 software (version 2.09). To
calculate the percentage of protein adsorbed on aluminium phosphate,
the fluorescence of the supernatant was subtracted from the fluores-
cence of the amount of protein that was present initially.
2.8. Vaccine preparation
Seven formulations were made to study the adaptive immune re-
sponse in vivo. Each formulation contained 1.7mg/mL Al3+ aluminium
phosphate microparticles or aluminium phosphate nanoparticles in
combination with 100mM stabiliser as adjuvant and 10 μg/mL (3 Lf/
mL) diphtheria toxoid as antigen. The pH was set to pH 7.4 by using 0.1
and 0.01M NaOH and HCl. The osmolality was adjusted to 290 mOsm
by adding an appropriate volume of 700mM sucrose solution.
2.9. Adsorption degree of diphtheria toxoid
The amount of diphtheria toxoid that was adsorbed to aluminium
phosphate in the vaccines was determined by using an enzyme-linked
immuno sorbent assay (ELISA). A volume of 1.5 mL of each vaccine
formulation was centrifuged at 13,000g for 15min. Supernatants were
analysed for diphtheria toxoid content. To this end, ELISA plates (clear
flat-bottom high binding microplates, Greiner Bio-One) were coated
overnight at room temperature with 100 μL/well of 0.6 AU/mL horse
anti-diphtheria (produced in house) in 0.04M sodium carbonate, pH
9.6. Plates were incubated with two-fold serial dilutions (100 μL/well)
of the supernatants in phosphate buffered saline, pH 7.2, containing
1.06mM KH2PO4, 155mM NaCl, 2.97mM Na2HPO4 (PBS, Gibco,
Thermo Fisher Scientific) with 0.05% (v/v) polysorbate 80 at 37 °C for
two hours. On each plate, the original toxoid DIF04-44 was used to set
up a calibration curve with a range of 0.002–0.3 Lf/mL. Plates were
washed with 0.05% (v/v) polysorbate 80 in distilled water and in-
cubated with 100 μL/well of horse anti-diphtheria toxoid conjugated to
horseradish peroxidase (produced in house) which was 3,000x diluted
in PBS supplemented with 0.05% (v/v) polysorbate 80 and 0.5% (w/v)
Protifar (Nutricia) at 37 °C for 1.5 h. Plates were washed twice with
0.05% (v/v) polysorbate 80 in distilled water and incubated with
100 μL/well peroxidase substrate (Sure Blue TMB Microwell Peroxidase
Substrate, SeraCare Life Sciences) at room temperature for ten minutes.
The reaction was stopped by addition of 100 μL/well 0.2M H2SO4
(Sigma). The absorbance was read at 450 nm with a plate reader (Bio-
Tek reader EL808). Toxoid concentrations were calculated with
GraphPad Prism version 7.01. To calculate the adsorption degree of
diphtheria toxoid to aluminium phosphate nanoparticles, the amount
diphtheria toxoid that was present in each supernatant was subtracted
from the amount of diphtheria toxoid that was added.
2.10. Immunisation study
The animal experiment was in agreement with the Animal Research:
Reporting of in vivo Experiments guidelines and was approved by an
independent ethical committee (the animal experiments committee
(DEC) of the National Institute for Public Health and the Environment
(RIVM)) and the central committee animal studies (The Hague, the
Netherlands), following the procedures of the European legislation
guideline (2010/63/EU) and the Dutch law for animal testing (WOD).
Specific pathogen-free BALB/c mice (Charles River), 8 weeks old,
were divided in groups of 10 animals which consisted of five males and
five females and housed per gender and per group. All mice received a
single dose containing 0.85mg Al3+, 1.5 Lf DIF04-44 and 50 μmol
amino acid in a total volume of 500 μL via subcutaneous injection in the
left groin on day 0 and 21. Animals were sacrificed on day 35. Blood
was collected in blood collection tubes (MiniCollect 0.8 ml Z Serum Sep
GOLD, Greiner Bio-One), and serum was obtained and stored at −20 °C
after centrifugation (ten minutes, 3000g).
2.11. Diphtheria toxoid specific IgG ELISA
Diphtheria toxoid-specific immunoglobulin G (IgG) titres in mouse
sera were determined by an ELISA. ELISA plates were coated overnight
at room temperature with 100 μL/well of 0.5 Lf/mL diphtheria toxoid
in 0.04M sodium carbonate, pH 9.6. Plates were washed with 0.05%
(v/v) polysorbate 80 (Merck) in distilled water and blocked with 1%
(w/v) BSA (Serva) in PBS at 37 °C for one hour. Plates were washed
with 0.05% (v/v) polysorbate 80 in distilled water and incubated with
100 μL/well two-fold serial dilutions of individual sera in PBS with
0.05% (v/v) polysorbate 80 in ultrapure water at 37 °C for two hours.
On each plate, the monoclonal antibody DIM-9 (made in house) was
added as a reference. Plates were washed with 0.05% (v/v) polysorbate
80 in distilled water and incubated with 100 μL/well of goat anti-mouse
IgG (Southern Biotech) which was 4,000x diluted in PBS supplemented
with 0.05% (v/v) polysorbate 80 and 0.5% Protifar (Nutricia) at 37 °C
for 1.5 h. Plates were washed twice with 0.05% (v/v) polysorbate 80 in
distilled water and incubated with 100 μL/well peroxidase substrate
(Sure Blue TMB Microwell Peroxidase Substrate, SeraCare Life
Sciences) at room temperature for ten minutes. The reaction was
stopped by addition of 100 μL/well 0.2M H2SO4 (Sigma). The absor-
bance was read at 450 nm with a plate reader (Bio-Tek reader EL808).
Antibody titres were expressed as the log10 of the serum dilution giving
50% of the maximum optical density at 450 nm for each individual
curve and normalised to the titre of aluminium phosphate nanoparticles
using GraphPad Prism version 7.01.
2.12. Toxin neutralisation test
The diphtheria toxin neutralising capacity of the mouse sera was
determined by using a toxin neutralisation test. Sera were inactivated
by heating at 56 °C for 45min and stored at −20 °C. Individual sera
were diluted two-fold in complete culture medium (Minimum Essential
Media 199 with Hanks’ salts and L-glutamine, without sodium bi-
carbonate (Sigma Aldrich) supplemented with 1 g/L glucose (Gibco,
Thermo Fisher Scientific), 1.6 mM glutamine, 1.7 g/L sodium bicarbo-
nate (Gibco, Thermo Fisher Scientific), 5% foetal bovine serum (Serana)
and 100 U/mL penicillin and streptomycin (Gibco, Thermo Fisher
Scientific)) in 96-well culture plates. Next, 50 μL/well 0.001 Lf/mL
diphtheria toxin (Dt125, produced in house) diluted in complete culture
medium was added and plates were incubated at 37 °C and 5% CO2 for
two hours. Then, 50 μL suspension of Vero cells were added so that each
well contained 12,500 cells. Plates were incubated at 37 °C and 5% CO2
for six days. Cell viability was determined using an MTT-based cell
proliferation kit (Roche) according to the manufacturer’s instructions.
Neutralising antibody titres were expressed as the log2 of the first serum
dilution giving 80% of the maximum optical density at 570 nm for each




3.1. Physicochemical properties of aluminium phosphate nanoparticles
The original size of aluminium phosphate was 1455 ± 145 nm with
a polydispersity index (PdI) of 0.229 ± 0.036 (Fig. 1A). Sonication for
60 s at 10% or 50% intensity resulted in a reduced size of 404 ± 2 nm
or 324 ± 1 nm, respectively (Fig. S1). Sonication at 70%, which was
the maximum intensity for the specific tip used, resulted in a fast re-
duction in size with the biggest reduction taking place during the first
15 s (Fig. 1A). After 60 s, the size of aluminium phosphate was reduced
to 273 ± 8 nm. The corresponding PdI was 0.197 ± 0.011, indicating
that the particle population was relatively monodisperse. Therefore, in
following experiments, sonication was performed at an intensity of
70%. The PdI increased within the first 20 s of sonication. This indicates
the generation of particles with different sizes as a result of sonication.
After this increase, the PdI decreased, indicating a more homogenous
size distribution. Although longer sonication may result in smaller
particles, this also enhances tip erosion, introducing contamination
from the tip material being present in the sonicated dispersion.
Therefore, the maximum sonication time was set at 60 s.
In addition to the size, the point of zero charge (PZC) of aluminium
phosphate was determined. Sonication did not change the PZC, which
was approximately 4.5 before and after sonication (Fig. 1B). In sub-
sequent experiments, a pH of 7.4 was used to mimic physiological pH.
3.2. Stabilisation of aluminium phosphate nanoparticles
To investigate the colloidal stability of aluminium phosphate na-
noparticles, the size was monitored for 15 weeks under physiological
conditions, i.e. pH 7.4, 290 mOsm (Fig. 2). Within 24 h after sonication,
the size increased by a factor of two (215%) compared to the size di-
rectly after sonication: from 284 ± 9 nm to 718 ± 10 nm. Between
days 1 and 106 the size of sonicated aluminium phosphate still in-
creased, albeit not as fast as in the first 24 h. The size was increased to
895 nm after 106 days. PdI values of all samples with sizes below
1000 nm were between 0.1 and 0.2 (Fig. S4), indicating relatively
monodisperse size populations.
To improve the stability of nanoparticles, 26 compounds that are
known for their interaction with and/or stabilising effects of colloids,
i.e. amino acids, detergents, buffers, sugar alcohols and surfactants,
were studied for their stabilising properties. Screening experiments
(Table S 1, Fig. S2, Table S2 and Fig. S3) showed that amino acids
affected the aggregation of sonicated aluminium phosphate particles
the most. For example, the presence of histidine resulted in a size of
620 ± 9 nm, while the presence of glutamic acid induced aggregation
of aluminium phosphate nanoparticles resulting in particles with a size
of 1102 ± 40 nm. Therefore, an extensive study was performed to in-
vestigate the effects of amino acids on the particle size of sonicated
aluminium phosphate. The buffering capacity of aluminium phosphate
was used to keep the pH at 7.4.
After 106 days incubation, the size of aluminium phosphate in the
presence of threonine and LAPA, 465 ± 2 nm and 434 ± 5 nm, re-
spectively, was slightly smaller than that of aluminium phosphate na-
noparticles in absence of amino acids (Fig. 2, Fig. S4). The nano-
particles increased the most in the presence of arginine
(1462 ± 91 nm), aspartic acid (1049 ± 29 nm) and glutamic acid
(1429 ± 243 nm), indicating destabilisation by these amino acids.
The presence of excipients in a suspension may alter the zeta po-
tential of sonicated aluminium phosphate, leading to decreased or in-
creased aggregation propensity of the particles. Therefore, the zeta
potential of aluminium phosphate nanoparticles was measured in the
presence of the amino acids (Fig. 2). The zeta potential of non-stabilised
aluminium phosphate nanoparticles was −13.2 ± 2.4mV. Most amino
acids had limited effect on the zeta potential of the nanoparticles.
However, in the presence of lysine the zeta potential became more
negative, i.e. −27.8 ± 3.4mV, which is a notably more negative po-
tential than observed with the other amino acids. The zeta potential of
sonicated aluminium phosphate approached −8mV in the presence of
arginine and histidine.
Alterations in zeta potential did not always correlate to the altered
size. For example, the presence of arginine resulted in particles with a
zeta-potential of −7 ± 1mV and a size of 1462 ± 91 nm. The pre-
sence of histidine resulted in particles with a comparable zeta potential
of −9 ± 1mV. However, the corresponding size of the particles was
839 ± 23 nm. Hence, the effects on the stability could not only be
explained by an altered zeta potential compared to the zeta potential of
aluminium phosphate without amino acid.
3.3. In-depth study of stabilisation by particular amino acids
3.3.1. Influence of pH
The effects of arginine, asparagine, aspartic acid, threonine and
LAPA on the stability of aluminium phosphate nanoparticles were fur-
ther investigated at different pH values. The size and zeta potential of
the nanoparticles were monitored between pH 5 and 9 for one week.
The pH of the dispersion largely affected the size and zeta potential. For
example, the size of aluminium phosphate nanoparticles in the absence
of a stabiliser was smaller at pH 8.7 compared to the size at pH 5.7 on
day 1, 1491 ± 36 nm and 270 ± 2.4 nm, respectively. The corre-
sponding zeta potential gradually changed from −10.8 ± 1.6 nm at
pH 5.7 to −30.3 ± 0.5 nm at pH 8.7 on day 1 (Fig. 3). A similar
pattern was observed on day 7, indicating stability for at least one
week. The size of sonicated aluminium phosphate was not influenced
by asparagine, aspartic acid, threonine and LAPA. However, the size of
aluminium phosphate nanoparticles was increased in the presence of
Fig. 1. Particle size (A) and zeta potential (B) of aluminium phosphate before and after sonication. (A) Aluminium phosphate was sonicated at 70% of the
maximum power output, and at different duration. (B) Aluminium phosphate was sonicated at an intensity of 70% for 60 s. Data is presented as mean ± SD (n=3).
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arginine irrespective of the pH, varying from 1504 ± 140 nm at pH 5.3
to 636 ± 14 nm at pH 8.0 on day 1. The corresponding zeta potential
was −4 ± 1mV at pH 5.3 and −11 ± 3mV at pH 8.0 in the presence
of arginine. The zeta potential was −7 ± 1mV at pH 5.4 and
−29 ± 2mV at pH 8.9 in the presence of LAPA. Asparagine, aspartic
acid and threonine did not alter the size and zeta potential of the na-
noparticles. Although the zeta potential aluminium phosphate nano-
particles in the presence of LAPA was less negative compared to
without amino acid, no effects on size were detected. The zeta potential
was less negative in the presence of arginine, resulting in an increased
size. After one week, the effects of arginine, asparagine, aspartic acid,
threonine and LAPA on the size and zeta potential of aluminium
phosphate nanoparticles were not different compared to day 1. Thus,
the effects of the selected amino acids on the stability of aluminium
phosphate nanoparticles were largely affected by the pH of the solution.
Only arginine induced aggregation, which can be correlated to the less
negative zeta potential values.
3.3.2. Binding of amino acids to aluminium phosphate
Particular amino acids affect the stability of the aluminium phos-
phate nanoparticles, resulting in stabilisation or aggregation. The
binding of arginine, asparagine, aspartic acid, threonine and LAPA to
sonicated aluminium phosphate was investigated by measuring the
proportion of amino acid that was adsorbed to the sonicated aluminium
phosphate particles by RP-HPLC. Adsorption ranged from
7.0 ± 1.9 nmol/mg Al3+ for arginine to 17.8 ± 1.0 nmol/mg Al3+ for
threonine (Fig. 4). Threonine adsorbed with a significantly higher
amount to aluminium phosphate than asparagine, arginine and LAPA.
Arginine adsorbed significantly less to aluminium phosphate nano-
particles than aspartic acid, asparagine, threonine and LAPA. No sig-
nificant differences were found between adsorption of aspartic acid,
asparagine and LAPA to aluminium phosphate.
3.4. Effect of amino acid addition on protein adsorption
The adsorption capacity and adsorption strength are considered
Fig. 2. Size and zeta potential of sonicated
aluminium phosphate in the presence of
amino acids. Sonicated aluminium phosphate
was incubated at 37 °C in the presence of
50mM amino acid. The size was measured
weekly with DLS. Here, only the results ob-
tained at day 1 and day 106 are shown. All
measurements and PdI values can be found in
Supplemental Figure S 4. Dotted lines re-
present the size and zeta potential of alumi-
nium phosphate nanoparticles immediately
after sonication, 311 ± 4.1 nm and
−16 ± 2.6mV, respectively. Data is pre-
sented as mean ± SD (n=3).
Fig. 3. pH-stability of sonicated aluminium
phosphate in the absence or presence of
amino acids at pH 5–9 on day 1 (A and B)
and day 7 (C and D). Size: panels A and C;
zeta potential: panels B and D. Sonicated alu-
minium phosphate was incubated at 37 °C in
the presence of 50mM arginine, asparagine,
aspartic acid, threonine or LAPA for 7 days.
Data is presented as mean ± SD (n=3).
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important factors for the initiation of an immune response after vac-
cination [5]. The adsorption capacity of aluminium phosphate nano-
particles was studied by using the model protein lysozyme. The IEP of
lysozyme is 11.35 [20]. At physiological pH, aluminium phosphate and
lysozyme are oppositely charged, forming optimal adsorption circum-
stances. The adsorption capacity was 1.6 ± 0.2mg lysozyme/mg Al3+
ions for sonicated aluminium phosphate in the absence of a stabiliser.
This was not significantly higher than that of the original aluminium
phosphate (1.3 ± 0.3mg lysozyme/mg Al3+) (Fig. S5).
Addition of amino acids reduced the adsorption of lysozyme to
aluminium phosphate nanoparticles (Fig. 5). The highest adsorption
degree of the stabilised aluminium phosphate nanoparticles was mea-
sured in the presence of asparagine. The adsorption degree of lysozyme
to aluminium phosphate nanoparticles decreased even more in the
presence of LAPA, threonine, arginine and aspartic acid.
3.5. Effect of amino acid addition to aluminium phosphate on the adaptive
immune response against diphtheria toxoid
The immunogenicity of diphtheria toxoid in combination with alu-
minium phosphate nanoparticles in the presence of amino acids was
tested in vivo. Therefore, mice were injected twice with an experi-
mental diphtheria toxoid vaccine containing aluminium phosphate
nanoparticles in combination with either aspartic acid, asparagine,
threonine, arginine or LAPA. The size and zeta potential of the vaccines
as well as the adsorption degree of diphtheria toxoid were determined.
Aluminium phosphate nanoparticles aggregated to particles with a size
larger than 4000 nm in the presence of arginine, while the size of alu-
minium phosphate nanoparticles remained below 800 nm in the pre-
sence of asparagine, LAPA, threonine or aspartic acid (Fig. 6A). The
zeta potential of aluminium phosphate nanoparticles was negative in
the presence or absence of amino acids (Fig. 6A). Arginine reduced the
zeta potential from −38 ± 1.4mV to −11 ± 5.5mV. The adsorption
degree of diphtheria toxoid to aluminium phosphate varied from 83%
to 96% of the added amount of antigen (Fig. 6B). The amino acids did
not influence the adsorption degree significantly compared to that of
plain aluminium phosphate nanoparticles.
In order to assess the immunogenicity of diphtheria toxoid ad-
juvanted with stabilised aluminium phosphate nanoparticles, mice were
immunised on day 0 and 21. On day 35, mice were bled and their sera
were analysed for total anti-diphtheria toxoid IgG titres and diphtheria
toxin-neutralising antibodies. IgG titres of mice immunised with vac-
cines containing aluminium phosphate nanoparticles were significantly
increased by the addition of arginine. On average, small changes in the
diphtheria toxin-neutralising titres were detected, but none of them was
significantly different from those elicited by the aluminium phosphate
nanoparticles without amino acid (Fig. 7A and B).
4. Discussion
Aluminium salts are the major adjuvants applied in human vaccines.
Commonly used aluminium-containing adjuvants aggregate in water.
The adjuvant effect may be affected by the physicochemical properties
of the particles. For example, small particles may induce less local ir-
ritation compared to big particles. In addition, an increased surface
area, which can be obtained by decreasing particle size, may be related
to an increased adsorption capacity of antigen to aluminium salts. In
this regard, a smaller amount of nanosized adjuvant is needed to adsorb
an equal amount of antigen compared to microsized adjuvant, reducing
the side effects of aluminium salts. In this study, we prepared nano-
particles by sonication of commercially available aluminium phos-
phate. The nanoparticles showed long-term aggregation, which could
be partially prevented by addition of particular amino acids. Arginine,
asparagine, aspartic acid, LAPA and threonine were selected to study
their stabilisation effects more extensively. Arginine and threonine
were selected as controls, because arginine induced aggregation of
aluminium phosphate nanoparticles to micro particles while the ag-
gregation was minimal in the presence of threonine. Asparagine and
aspartic acid were chosen to investigate the effect of substitution of the
amide group with a carboxyl group. LAPA includes a phosphate group
that can exchange with the hydroxyl and phosphate groups on alumi-
nium phosphate, the so called ligand exchange. Together, this selection
may help to shed light on the mechanism of stabilisation of aluminium
phosphate nanoparticles.
Fig. 4. Interactions between amino acids and aluminium phosphate na-
noparticles. Sonicated aluminium phosphate containing 1.7mg/mL Al3+ ions
was mixed with 100 μM amino acid. Samples were incubated overnight and
centrifuged at 16,000 g. The adsorption of amino acids to aluminium phosphate
was determined by subtracting the amount of free amino acid in the super-
natant from the amount of amino acid that was added. Data is presented as
mean ± SD (n= 3). P-values were determined by one-way ANOVA with
Tukey’s multiple comparison test (*= p < 0.05, **= p < 0.01,
***= p < 0.001, ****= p < 0.0001).
Fig. 5. Influence of amino acids on the adsorption of lysozyme to alumi-
nium phosphate. Sonicated aluminium phosphate containing 0.85mg/mL
Al3+ ions was mixed with 50mM amino acid and 2.1mg/mL fluorescent-la-
belled lysozyme. Samples were incubated for one hour at room temperature and
centrifuged at 16,000g. The adsorption of lysozyme to aluminium phosphate
was determined by subtracting the amount of free lysozyme in the supernatant
from the amount of lysozyme that was added. Data is presented as mean ±
range (n=2).
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Fig. 6. Size (A), zeta potential (A) and ad-
sorption degree (B) of vaccines. The ad-
sorption degree was measured by centrifuga-
tion of the vaccines and determination of
diphtheria toxoid in the supernatants. Data is
presented as % adsorbed diphtheria toxoid
with 100% equals the added amount diph-
theria toxoid. Data is presented as mean ± SD
(n=3).
Fig. 7. Total anti-diphtheria IgG titres (A)
and neutralising antibodies (B) of sonicated
aluminium phosphate in absence of pre-
sence of amino acids. 8-week old BALB/c
mice (five female and five male mice, open and
closed symbols respectively per group) were
immunised s.c. with 500 μL containing 0.85mg
Al3+, 50mM amino acid and 1.5 Lf diphtheria
toxoid on day 0 and day 21. Mice were bled on
day 35 and sera were analysed for total anti-
diphtheria IgG and neutralising antibodies.
Data is expressed as log10 of the serum dilution
giving 50% of the maximum optical density at
450 nm normalised to the average titre of mice
immunised with plain aluminium phosphate
nanoparticles (A) or as log2 of the first serum
dilution giving 80% of the maximum optical
density at 570 nm for each individual curve
(B). P-values were determined by one-way
ANOVA with Tukey’s multiple comparison test
(*= p < 0.05, ****= p < 0.0001).
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In this study, the particle size of the aluminium phosphate salts was
monitored by using DLS. Although this is a convenient screening tool to
estimate the particle size in the nanometre size range, DLS is not very
accurate for polydisperse samples and may miss large micrometre-sized
aggregates of aluminium phosphate salts. Other techniques such as flow
imaging microscopy or nanoparticle tracking analysis may therefore
add relevant information about the particle size and its distribution
[21,22].
Stabilisation of colloids can be achieved through 1) electrostatic
stabilisation by formation of an electrical double layer around colloids,
2) steric stabilisation by adsorption of molecules to colloids, or 3) de-
pletion stabilisation by free molecules in the dispersion medium. From
the selected amino acids, arginine showed the most pronounced effects.
The charge of arginine (pI 10.76) is opposite to that of aluminium
phosphate nanoparticles (PZC 4.5) at pH 7.4. The decreased absolute
zeta potential indicates that arginine forms a shield around aluminium
phosphate nanoparticles, which is likely based on electrostatic inter-
actions. Although this sometimes leads to electrostatic stabilisation,
arginine induced aggregation instead of stabilisation. This may be in-
duced by the formation of bridges between the positively charged ar-
ginine and the negatively charged aluminium phosphate nanoparticles.
Indeed, the guanidinium groups of arginine and phosphate groups form
salt bridges based on their electrostatic charge, leading to an almost
covalent-like stability [23].
We investigated the interactions between amino acids and alumi-
nium phosphate nanoparticles by analysis of the adsorption of amino
acids to aluminium phosphate. Although LAPA contained phosphate
groups that could contribute to ligand exchange with aluminium
phosphate, this did not enhance adsorption of this compound compared
to other amino acids. Amino acids are amphiprotic molecules and the
investigated amino acids have both positively charged amine groups
and negatively charged carboxyl groups. Thus, it is possible that the
adsorption of the amino acids to aluminium phosphate nanoparticles is
based on electrostatic interactions. In addition, the amino acids may be
trapped within the porous structure of aluminium phosphate during the
de-aggregation and re-aggregation of aluminium salts [24,25]. The
adsorption of arginine was remarkably reduced compared to the other
amino acids. This may be due to the formation of salt bridges between
arginine and aluminium phosphate nanoparticles, preventing the
formed micro particles from de-aggregation so that pores in which the
amino acid can be trapped are not exposed.
Although the extent of protein adsorption was not influenced by
sonication, the particle size might influence the immune response. For
example, the mechanism of uptake is different for micro particles
compared to nanoparticles. Li et al. showed that aluminium hydroxide
nanoparticles showed a stronger antigen-specific vaccine adjuvant ac-
tivity compared to aluminium hydroxide nanoparticles in vivo [16].
However, in this study there was no effect of sonication of aluminium
phosphate on the adaptive immune response against diphtheria toxoid
as shown by total anti-diphtheria IgG titres and toxin-neutralising an-
tibody titres. This may be due to the local environment at the injection
site, where salts that are present in body fluid may induce aggregation
of the nanoparticles. In addition, biomolecules that are present in bio-
logical fluids may interact with the nanoparticles, forming a protein
corona. The formation of a protein corona depends on the charge and
stability of the colloidal particle [26,27]. Because the presence of amino
acids altered the zeta potential of aluminium phosphate nanoparticles
(Fig. 3), it is likely that the protein corona was also affected. This may
have influenced the immune response in vivo.
The uptake of antigen by APCs is enhanced by poly-L-arginine after
s.c. injection [28]. Although we did not use poly-L-arginine in our
study, the presence of arginine in the formulation increased the total
anti-diphtheria toxoid IgG titres significantly compared to plain alu-
minium phosphate nanoparticles, Nevertheless, the titres in this study
were also more heterogeneous, which is undesirable. This is possibly
related to the aggregation of aluminium phosphate nanoparticles in the
presence of arginine, which caused a more heterogeneous size dis-
tribution. On the contrary, diphtheria-neutralising antibody titres did
not increase in the presence of arginine. An increased total IgG titre is
thus in this case not related to an improved functional immune re-
sponse.
The current study demonstrates the effective size reduction of alu-
minium phosphate by sonication. While the obtained aluminium
phosphate nanoparticles aggregated, long-term aggregation was effec-
tively prevented by addition of threonine, asparagine, aspartic acid or
LAPA. Sonication and the addition of amino acids did not affect the
adaptive immune response induced by aluminium phosphate nano-
particles in combination with diphtheria toxoid, except for arginine
which increased total IgG titres but not diphtheria-neutralising anti-
bodies. By applying sonication to the aluminium phosphate micro
particles and stabilising the obtained aluminium phosphate nano-
particles, a functional vaccine adjuvant with altered physicochemical
properties was obtained. Coating of the nanoparticles with functional
groups, such as amino acids, will shed light on the mechanism of action
of the adjuvant and may reveal options to improve the current ad-
juvant. This may ultimately help to develop a new generation alumi-
nium salt-based adjuvants with improved performance compared to the
currently used aluminium-containing adjuvants.
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